Eduardo Nobile‐Orazio
A5032510994- Peripheral Neuropathies and Disorders
- Hereditary Neurological Disorders
- Myasthenia Gravis and Thymoma
- Monoclonal and Polyclonal Antibodies Research
- Peripheral Nerve Disorders
- Multiple Myeloma Research and Treatments
- Multiple Sclerosis Research Studies
- Autoimmune Neurological Disorders and Treatments
- Pain Mechanisms and Treatments
- Nerve injury and regeneration
- Long-Term Effects of COVID-19
- Amyotrophic Lateral Sclerosis Research
- Botulinum Toxin and Related Neurological Disorders
- Toxin Mechanisms and Immunotoxins
- Glycosylation and Glycoproteins Research
- Autoimmune Bullous Skin Diseases
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- SARS-CoV-2 and COVID-19 Research
- Pharmacological Effects of Natural Compounds
- Systemic Lupus Erythematosus Research
- Neurogenetic and Muscular Disorders Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Heparin-Induced Thrombocytopenia and Thrombosis
- Complement system in diseases
IRCCS Humanitas Research Hospital
2007-2025
Humanitas University
2015-2024
University of Milan
2015-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2014-2024
Erasmus MC
2021-2023
Aarhus University Hospital
2022-2023
Mylan (South Africa)
2002-2023
Institute of Neuroimmunology of the Slovak Academy of Sciences
2020-2023
University of Michigan
2023
Daiichi Sankyo (United States)
2022
Background: Consensus guidelines on the definition, investigation, and treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have been previously published in European Journal Neurology Peripheral Nervous System . Objectives: To revise these guidelines. Methods: Disease experts, including a representative patients, considered references retrieved from MEDLINE Cochrane Systematic Reviews between August 2004 July 2009 prepared statements that were agreed an iterative...
This multicenter, randomized, double-blind, crossover trial compared a six week course of oral prednisolone tapering from 60 mg to 10 daily with intravenous immunoglobulin (IVIg) 2.0 g/kg given over one two days for treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Twenty-four the thirty-two randomized patients completed both treatment periods. Both treatments produced significant improvements in primary outcome measure, change an 11-point disability scale weeks...
To revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Seventeen disease experts, a patient representative, and two Cochrane methodologists constructed 12 Population/Intervention/Comparison/Outcome (PICO) questions regarding diagnosis treatment to guide literature search. Data were extracted summarized in GRADE summary of findings (for PICOs) or evidence tables diagnostic PICOs). Statements prepared according Evidence-to-Decision...
To revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).Seventeen disease experts, a patient representative, and two Cochrane methodologists constructed 12 Population/Intervention/Comparison/Outcome (PICO) questions regarding diagnosis treatment to guide literature search. Data were extracted summarized in GRADE summary of findings (for PICOs) or evidence tables diagnostic PICOs).Statements prepared according Evidence-to-Decision frameworks....
Guillain-Barré syndrome is a heterogeneous disorder regarding the clinical presentation, electrophysiological subtype and outcome. Previous single country reports indicate that may differ among regions, but no systematic comparative studies have been conducted. Comparative are required to identify factors determining disease susceptibility, variation prognosis, improve diagnostic criteria. The International Syndrome Outcome Study prospective, observational cohort study including all patients...
In patients with Multiple Sclerosis (pwMS) disease-modifying therapies (DMTs) affects immune response to antigens. Therefore, post-vaccination serological assessments are needed evaluate the effect of vaccine on SARS-CoV-2 antibody response.We designed a prospective multicenter cohort study enrolling pwMS who were scheduled for SARS-Cov-2 vaccination mRNA vaccines (BNT162b2, Pfizer/BioNTech,Inc or mRNA-1273, Moderna Tx,Inc). A blood collection before first dose and 4 weeks after second was...
Single cases and small series of Guillain-Barré syndrome (GBS) have been reported during the SARS-CoV-2 outbreak worldwide. We evaluated incidence clinical features GBS in a cohort patients from two regions northern Italy with highest number COVID-19.GBS diagnosed 12 referral hospitals Lombardy Veneto March April 2020 were retrospectively collected. As control population, 2019 same considered.Incidence was 0.202/100 000/month (estimated rate 2.43/100 000/year) vs 0.077/100 0.93/100 months...
To assess the prevalence and isotypes of anti-nodal/paranodal antibodies to nodal/paranodal proteins in a large chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) cohort, compare clinical features seronegative vs seropositive patients, gather evidence their isotype-specific pathogenic role.
Guillain-Barré syndrome (GBS) is an acute polyradiculoneuropathy. Symptoms may vary greatly in presentation and severity. Besides weakness sensory disturbances, patients have cranial nerve involvement, respiratory insufficiency, autonomic dysfunction pain. To develop evidence-based guideline for the diagnosis treatment of GBS, using Grading Recommendations, Assessment, Development Evaluation (GRADE) methodology a Task Force (TF) European Academy Neurology (EAN) Peripheral Nerve Society (PNS)...
BackgroundIn this study we aimed to monitor the risk of breakthrough SARS-CoV-2 infection in patients with MS (pwMS) under different DMTs and identify correlates reduced protection.MethodsThis is a prospective Italian multicenter cohort study, long-term clinical follow-up CovaXiMS (Covid-19 vaccine Multiple Sclerosis) study. 1855 pwMS scheduled for mRNA vaccination were enrolled followed up mean time 10 months. The cumulative incidence Covid-19 cases was calculated before after December...
We studied the frequency and clinical correlates of different IgM specificities in 75 patients with neuropathy associated monoclonal gammopathy. Patients were tested for reactivity myelin-associated glycoprotein, P0, neurofilaments, tubulin by immunoblot; GM1, asialo-GM1, GM2, GD1a, GD1b, sulfatide, chondroitin sulfate C enzyme-linked immunosorbent assay; brain nerve glycolipids overlay high-performance thin-layer chromatography. Forty-two (56%) had high titers antibodies to MAG; 4 (5%),...
Numerous sets of diagnostic criteria have sought to define chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and randomized trials systematic reviews treatment been published. The objective is prepare consensus guidelines on the definition, investigation CIDP. Disease experts a patient representative considered references retrieved from MEDLINE Cochrane Systematic Reviews in May 2004 prepared statements which were agreed an iterative fashion. Task Force good practice points...
Prognostic significance of hyperglycemia on short-term survival was evaluated in 72 patients with acute hemispheric stroke. All were admitted within 48 hours onset, and the neurologic deficit assessed by means a standardized score. A computed tomogram taken all cases admission. Mortality higher hyperglycemic no history diabetes mellitus (78%) than diabetic (45%) normoglycemic nondiabetic (29%) patients. In patients, glucose level correlated score lesion size tomogram. Reactive due to major...
Many data point to a pathogenetic role for IgM antibodies the myelin-associated glycoprotein (MAG) in neuropathy associated with monoclonal gammopathy, supporting use of immune therapies affected patients. Almost 50% patients have been reported improve these therapies, but effect treatment on long-term prognosis remains unclear. We analysed outcome 25 26 (mean age at entry 65 years, range 45–85 years) and high anti-MAG IgM, first examined by us between 1984 1994. By January 1999, after mean...
In order to clarify the role of angiogenic factors in polyneuropathy POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes) syndrome, we measured serum concentrations vascular endothelial growth factor (VEGF) and erythropoietin (EPO) 11 patients correlated these with VEGF EPO peripheral nerve expression degree endoneurial vessel involvement. We found that syndrome was associated high levels and, conversely, low EPO. Similarly, nerves highly expressed blood...
We investigated the role of complement in pathogenesis demyelinating polyneuropathy that occurs some patients with IgM monoclonal gammopathy. Seven chronic sensorimotor and gammopathy were examined. In six patients, protein recognized an epitope shared by myelin-associated glycoprotein two peripheral-nerve glycolipids, whereas one patient, bound to unidentified myelin antigen. Direct indirect immunofluorescence immunoperoxidase assays showed colocalization along sheaths fibers components...
Peripheral neuropathy was found in 12 (46%) of 26 patients with macroglobulinemia. The subclinical two. Anti-myelin-associated glycoprotein (MAG) activity six (50%) neuropathy. Sural nerve biopsies showed demyelination and IgM deposits on the myelin sheath. In one patient who had no anti-MAG activity, serum bound to peripheral by indirect immunofluorescence several protein bands other tissues immunoblot. five neuropathy, we binding M proteins components, but three there were endoneurial...
Some patients with neuropathy have IgM M-proteins that bind to myelin and myelin-associated glycoprotein (MAG). We compared the binding properties of a human anti-MAG M-protein three mouse monoclonal antibodies (GEN-S1, GEN-S3, GEN-S8) antibody (HNK-1) binds both MAG natural killer cells. The GEN-S1, GEN-S8 bound different epitopes in polypeptide portion as shown by peptide mapping, deglycosylation competitive studies. M protein HNK-1 CNS PNS several additional bands 70K, 30K, 26K, 23K...
In an unselected series of patients with monoclonal gammopathy undetermined significance (MGUS) we found neuropathy in 2 34 IgG (6%), 14 IgA (14%), and 8 26 IgM MGUS (31%). The was subclinical 6 (1 IgG, 1 IgA, 4 IgM). Patients or had a prominent motor impairment electrophysiologic morphologic findings suggestive predominant axonal degeneration. No deposit the M-protein sural nerve no reactivity detected these patients. sensory evidence demyelination. reacted myelin-associated glycoprotein...
Objectives A few variants of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have been described, but their frequency and evolution to typical CIDP remain unclear. To determine the characteristics variants, possible CIDP, treatment response. Methods We applied a set diagnostic criteria 460 patients included in database Italian with CIDP. Clinical response were reviewed for each patient. The Kaplan-Meier curve was used estimate progression rate from atypical Results At time...
Objectives: We performed responsiveness comparison between the patient-reported Inflammatory Rasch-built Overall Disability Scale (I-RODS) and widely used clinician-reported Neuropathy Cause Treatment–Overall Limitation (INCAT-ONLS) in patients with Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), immunoglobulin M–monoclonal gammopathy of undetermined significance related polyneuropathy (IgM-MGUSP). Methods: One hundred thirty-seven (GBS: 55,...